Fennec Pharmaceuticals Inc. (FENC): Operating Cash Flow
-$12.47M
Year ended 2025-12-31
-$2.04M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$12.47M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $26.98M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$17.14M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$18.06M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$14.22M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$15.60M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$9.06M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | -$7.83M | n/m | 2020-02-14, From 2018-01-01 |
| 2017-12-31 | -$3.64M | n/m | 2019-03-15, From 2017-01-01 |
| 2016-12-31 | -$2.12M | n/m | 2018-03-28, From 2016-01-01 |
| 2015-12-31 | -$1.86M | n/m | 2017-03-29, From 2015-01-01 |
| 2014-12-31 | -$1.70M | n/m | 2015-03-31, From 2014-01-01 |
| 2013-12-31 | -$2.21M | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$2.99M | n/m | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | -$3.23M | n/m | 2013-04-01, From 2011-01-01 |
| 2010-12-31 | -$1.93M | n/a | 2012-03-27, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | -$12.47M | n/m |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | -$165.24M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$132.47M | n/m |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$97.21M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | -$232.89M | n/m |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | -$11.99M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$58.13M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$98.69M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$85.62M | n/m |
Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗